治療に抵抗する統合失調症患者におけるクロザピンの投与量減少:症例シリーズ
Mohammed A Alarabi1,2, Akash Prasanna Kumar1, Valerie Powell1
1Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), 1051 Queen Street West, Toronto, Ontario M6J 1H3, Canada.
Schizophrenia bulletin
|August 22, 2025
まとめ
治療抵抗性統合失調症 (TRS) の患者におけるクロザピンの投与量を減らすと,再発のリスクが高くなります. クロザピンの濃度に従って徐々に投与量を減らすことで,このリスクを軽減することができるが,より大規模な研究が必要である.
科学分野:
- 精神科
- 薬理学について
- 臨床医学
背景:
- 寛解した治療抵抗性統合失調症 (TRS) 患者におけるクロザピンの処方停止に関する証拠は限られている.
- この研究では,TRS患者で寛解を達成したクロザピンの投与量減少が検討されています.
研究 の 目的:
- 治療に抵抗する統合失調症が寛解した患者のクロザピンの投与量減少の結果を調査する.
- クロザピンの処方停止に関連した再発のリスクを評価する.
主な方法:
- クロザピンで治療された9人のTRS患者の経歴を振り返る.
- 含有基準:TRS診断,クロザピンの寛解,および>25%の維持用量減少.
- 寛解状態,再発,クロザピンの濃度,および投与量減少率に関するデータが収集されました.
主要な成果:
- 患者の44. 4%が投与量減少後も寛解状態を維持した.
- 33. 3%が再発し,投与量を増やす必要があり,22. 2%が再発し,入院した.
- 緩やかな収縮率 (例えば12週間に25mg) が観察され,緩やかな収縮率は寛解の持続と関連している可能性がある.
結論:
- 寛解したTRS患者におけるクロザピンの投与量減少は,重発の重大なリスクを伴います.
- クロザピンの濃度に従って数ヶ月から数年の間,徐々に投与量を減らすことで,再発のリスクが低下する可能性があります.
- クロザピンの処方停止を受けたTRS患者の再発予測要因を特定するために,より大きなコホートでのさらなる研究が必要である.
関連する概念動画
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Drug Therapy
97
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
97
Psychosis and Antipsychotic Drugs: Overview
454
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
454
Antipsychotic Drugs: Typical and Atypical Agents
314
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
314
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
296
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
296
Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344


